Cargando…

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

AIMS/HYPOTHESIS: Higher plasma concentrations of tumour necrosis factor receptor (TNFR)-1, TNFR-2 and kidney injury molecule-1 (KIM-1) have been found to be associated with higher risk of kidney failure in individuals with type 2 diabetes in previous studies. Whether drugs can reduce these biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sen, Taha, Li, Jingwei, Neuen, Brendon L., Neal, Bruce, Arnott, Clare, Parikh, Chirag R., Coca, Steven G., Perkovic, Vlado, Mahaffey, Kenneth W., Yavin, Yshai, Rosenthal, Norman, Hansen, Michael K., Heerspink, Hiddo J. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423682/ https://www.ncbi.nlm.nih.gov/pubmed/34415356 http://dx.doi.org/10.1007/s00125-021-05512-5

Ejemplares similares

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program
por: Young, Tamara K., et al.
Publicado: (2021)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
por: Wang, Katherine M., et al.
Publicado: (2021)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
por: Koshino, Akihiko, et al.
Publicado: (2022)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2019)

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
por: Zhou, Zien, et al.
Publicado: (2019)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018)

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
por: Ohkuma, Toshiaki, et al.
Publicado: (2020)

Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
por: Zhou, Zien, et al.
Publicado: (2019)

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
por: Neal, Bruce, et al.
Publicado: (2017)

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
por: Ferrannini, Giulia, et al.
Publicado: (2023)

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
por: Neal, Bruce, et al.
Publicado: (2017)

Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis
por: Siegmund, Daniela, et al.
Publicado: (2016)

TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages
por: Wajant, Harald, et al.
Publicado: (2019)

Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling
por: Siegmund, Daniela, et al.
Publicado: (2023)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Transmembrane TNF and Its Receptors TNFR1 and TNFR2 in Mycobacterial Infections
por: Ruiz, Andy, et al.
Publicado: (2021)

Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis
por: Fiedler, Timon, et al.
Publicado: (2023)

Gut region-specific TNFR expression: TNFR2 is more affected than TNFR1 in duodenal myenteric ganglia of diabetic rats
por: Barta, Bence Pál, et al.
Publicado: (2023)

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
por: Mahaffey, Kenneth W., et al.
Publicado: (2019)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Precambrian origins of the TNFR superfamily
por: Quistad, S D, et al.
Publicado: (2016)

TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms
por: Rauert, H, et al.
Publicado: (2011)

Differential Expression, Shedding, Cytokine Regulation and Function of TNFR1 and TNFR2 in Human Fetal Astrocytes
por: Choi, Sun Ju, et al.
Publicado: (2005)

Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer
por: Martínez-Reza, Isela, et al.
Publicado: (2017)

Alleviation of Ultraviolet-B Radiation-Induced Photoaging by a TNFR Antagonistic Peptide, TNFR2-SKE
por: Lee, Kyoung-Jin, et al.
Publicado: (2019)

Leukocyte TNFR1 and TNFR2 Expression Contributes to the Peripheral Immune Response in Cases with Ischemic Stroke
por: Hansen, Rikke B., et al.
Publicado: (2021)

Distinct Role of TNFR1 and TNFR2 in Protective Immunity Against Orientia tsutsugamushi Infection in Mice
por: Liang, Yuejin, et al.
Publicado: (2022)

The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy
por: Takahashi, Hiroyuki, et al.
Publicado: (2022)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

TNFR2: The new Treg switch?
por: Cohen, José L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_64n4cr5q40mf641h78god2hecl